Transfusion related acute lung injury (TRALI) in cardiac surgery patients: incidence, risk factors and underlying pathophysiology

Transfusion related acute lung injury (TRALI) in cardiac surgery patients: incidence, risk factors and underlying pathophysiology - TRALI in cardiac surgery patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30078

Enrollment

1500

Registered

2006-11-10

Start date

2006-09-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloedtransfusie reacties Transfusion Reaction

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cardiac surgery patient with post operative ICU admittance Informed consent >18 years

Exclusion criteria

Exclusion criteria: Immunosupressive drugs

Design outcomes

Primary

Measure	Time frame
Riskfactors for TRALI (Type of operation, medical history, intoxications etc.) Incidence of TRALI in this cohort group Donors: Anti HLA/HNA antibodies in the donor blood Pro-inflammatory cytokines (TNF-x, IL-1, IL-6, IL-8) and bio acrive lipids in the transfusions. Patients: Biomarkers (CC10, SP-D, SP-A en KL-6), Pro-inflammatory cytokines, complement concentration, activity of the coagulation and fibrinolysis (TF, Factor VIIa, TATc, PAI-1, t-PA). Surfactant protein A and D, Clara cell protein and KL-6.	—

Measure

Time frame

Riskfactors for TRALI (Type of operation, medical history, intoxications etc.) Incidence of TRALI in this cohort group Donors: Anti HLA/HNA antibodies in the donor blood Pro-inflammatory cytokines (TNF-x, IL-1, IL-6, IL-8) and bio acrive lipids in the transfusions. Patients: Biomarkers (CC10, SP-D, SP-A en KL-6), Pro-inflammatory cytokines, complement concentration, activity of the coagulation and fibrinolysis (TF, Factor VIIa, TATc, PAI-1, t-PA). Surfactant protein A and D, Clara cell protein and KL-6.

—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results